Antibody-drug conjugates payloads: then, now and next
Drug Target Review
OCTOBER 4, 2023
7 These inhibitors have faced challenges such as dose-limiting toxicity and poor pharmacokinetics, but geldanamycin ADCs have demonstrated increased survival in mice. 10 Proteasome inhibitors Since the approval of Bortezomib in 2003, 11 new proteasome inhibitors have emerged with reduced side effects.
125 
Let's personalize your content